ViRexx Medical Corp. Receives U.S. Patent For Occlusin'TM' Embolotherapy

ViRexx Medical Corp. (TSX:VIR) a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced that it has been granted U.S. Patent 6,960,352 entitled, "Compositions and Methods for Producing Vascular Occlusion Using a Solid-Phase Platelet Binding Agent". The patent broadly covers methods for treating vascularized tumors and hyperplastic tissues using solid-phase agents, such as particles, coils and stents, coated with von Willebrand factor.